3-(2-hydroxyethoxy)-4-methoxybenzoic acid methyl ester | 1081313-96-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(2-hydroxyethoxy)-4-methoxybenzoic acid methyl ester
• 英文别名: methyl 3-(2-hydroxyethoxy)-4-methoxybenzoate
• CAS: 1081313-96-3
• 化学式: C₁₁H₁₄O₅
• mdl: MFCD25955257
• 分子量: 226.229
• InChiKey: HKRBTYDTRAHZFL-UHFFFAOYSA-N

物化性质

• 沸点：
  364.9±27.0 °C(Predicted)
• 密度：
  1.194±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  16
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  65
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3,4-二氢-2H-吡喃 、 3-(2-hydroxyethoxy)-4-methoxybenzoic acid methyl ester 在 4-甲基苯磺酸吡啶 作用下， 以 二氯甲烷 为溶剂， 反应 32.0h， 以74%的产率得到4-methoxy-3-[2-(tetrahydropyran-2-yloxy)ethoxy]benzoic acid methyl ester
  参考文献：
  名称：

  Novel and potent inhibitors of stearoyl-CoA desaturase-1. Part I: Discovery of 3-(2-hydroxyethoxy)-4-methoxy-N-[5-(3-trifluoromethylbenzyl)thiazol-2-yl]benzamide

  摘要：

  A series of structurally novel stearoyl-CoA desaturase-1 (SCD-1) inhibitors has been identified by optimizing a hit from our corporate library. Preliminary structure-activity relationship (SAR) studies led to the discovery of the highly potent and orally bioavailable thiazole-based SCD-1 inhibitor, 3-(2-hydroxyethoxy)-4-methoxy-N-[5-(3-trifluoromethylbenzyl)thiazol-2-yl]benzamide (23a). (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.05.119
• 作为产物：
  描述：

  3-羟基-4-甲氧基苯甲酸甲酯 、 2-溴乙醇 在 potassium carbonate 作用下， 以 N,N-二甲基乙酰胺 为溶剂， 反应 8.0h， 以69%的产率得到3-(2-hydroxyethoxy)-4-methoxybenzoic acid methyl ester
  参考文献：
  名称：

  Novel and potent inhibitors of stearoyl-CoA desaturase-1. Part I: Discovery of 3-(2-hydroxyethoxy)-4-methoxy-N-[5-(3-trifluoromethylbenzyl)thiazol-2-yl]benzamide

  摘要：

  A series of structurally novel stearoyl-CoA desaturase-1 (SCD-1) inhibitors has been identified by optimizing a hit from our corporate library. Preliminary structure-activity relationship (SAR) studies led to the discovery of the highly potent and orally bioavailable thiazole-based SCD-1 inhibitor, 3-(2-hydroxyethoxy)-4-methoxy-N-[5-(3-trifluoromethylbenzyl)thiazol-2-yl]benzamide (23a). (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.05.119

文献信息

• ANTIVIRAL COMPOUNDS
  申请人：Alios BioPharma, Inc.

  公开号：US20160244460A1

  公开（公告）日：2016-08-25

  Disclosed herein are new antiviral compounds, together with pharmaceutical compositions that include one or more antiviral compounds, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a paramyxovirus viral infection with one or more small molecule compounds. Examples of paramyxovirus infection include an infection caused by human respiratory syncytial virus (RSV).

  本文披露了新的抗病毒化合物，以及包括一个或多个抗病毒化合物的药物组合物，以及合成这些化合物的方法。本文还披露了使用一个或多个小分子化合物改善和/或治疗副粘病毒病毒感染的方法。副粘病毒感染的例子包括由人类呼吸道合胞病毒（RSV）引起的感染。
• Antiviral compounds
  申请人：Alios BioPharma, Inc.

  公开号：US10358453B2

  公开（公告）日：2019-07-23

  Disclosed herein are new antiviral compounds, together with pharmaceutical compositions that include one or more antiviral compounds, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a paramyxovirus viral infection with one or more small molecule compounds. Examples of paramyxovirus infection include an infection caused by human respiratory syncytial virus (RSV).

  本文公开了新的抗病毒化合物，以及包括一种或多种抗病毒化合物的药物组合物和合成这些化合物的方法。本文还公开了用一种或多种小分子化合物改善和/或治疗副黏液病毒感染的方法。副粘病毒感染的例子包括由人类呼吸道合胞病毒（RSV）引起的感染。
• Novel and potent inhibitors of stearoyl-CoA desaturase-1. Part I: Discovery of 3-(2-hydroxyethoxy)-4-methoxy-N-[5-(3-trifluoromethylbenzyl)thiazol-2-yl]benzamide
  作者：Yoshikazu Uto、Tsuneaki Ogata、Jun Harada、Yohei Kiyotsuka、Yuko Ueno、Yuriko Miyazawa、Hitoshi Kurata、Tsuneo Deguchi、Nobuaki Watanabe、Toshiyuki Takagi、Satoko Wakimoto、Ryo Okuyama、Manabu Abe、Nobuya Kurikawa、Sayako Kawamura、Michiko Yamato、Jun Osumi

  DOI：10.1016/j.bmcl.2009.05.119

  日期：2009.8

  A series of structurally novel stearoyl-CoA desaturase-1 (SCD-1) inhibitors has been identified by optimizing a hit from our corporate library. Preliminary structure-activity relationship (SAR) studies led to the discovery of the highly potent and orally bioavailable thiazole-based SCD-1 inhibitor, 3-(2-hydroxyethoxy)-4-methoxy-N-[5-(3-trifluoromethylbenzyl)thiazol-2-yl]benzamide (23a). (C) 2009 Elsevier Ltd. All rights reserved.